Front & Back Matter
Andreia Albuquerque(Universidade do Porto), Yen‐Shen Lu(National Taiwan University Hospital), Chantelle Wilcox, Kuan‐Der Lee(Taipei Medical University Hospital), Daniel López‐Trabada, Sepp Kaul, Elena García‐Martín, Ilja Kubisch(Klinikum Chemnitz), Ann‐Lii Cheng(National Taiwan University), Han Chu Lee(Asan Medical Center), Ana Blanco(Fundación Pública Galega de Medicina Xenómica), Chih-Hung Hsu(Women's Hospital, School of Medicine, Zhejiang University), Danbi Lee(Ulsan College), Anna Lee-Brunner, Zhong-Zhe Lin, Felipe A. Calvo(Hospital General Universitario Gregorio Marañón), Miguel Carballo, Myoung Kuk Jang, James W. Denham(University of Newcastle Australia), Allison Kautto, Gudrun Stamminger(Klinikum Chemnitz), Yu‐Yun Shao(National Taiwan University), Georg Breier(University Hospital Carl Gustav Carus), Young‐Hwa Chung(Pusan National University), María Orera Clemente, Carmen Martı́nez(Hospital Universitario Virgen Macarena), Yu-Hsuan Kuo, Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Chiun Hsu(National Taiwan University Hospital), José A. G. Agúndez(Rede de Química e Tecnologia), N. Fersis(Klinikum Chemnitz), Allison Steigler(University of Newcastle Australia), Young‐Suk Lim(Asan Medical Center), M. J. Devesa, María Isabel Peligros Gómez, Kang Mo Kim(Ulsan College), Jeong Ah Kim(Chungnam National University), Don Lee(University of Maryland, Baltimore), Cristina Fernández, Manuel Díaz‐Rubio, Chi-Huang Hsiao, Yung Sang Lee(The University of Texas at Dallas), Yin-Chun Shen, José M. Ladero, Sara Custodio Cabello, Ulrich Stölzel, Astrid Eichler(Goethe University Frankfurt), Chien‐Chung Huang(Centre National de la Recherche Scientifique), Yoon Seon Lee
Cited by 0
Related Papers
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
|Nature|1996|4.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
|Nature|1992|2.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k